Coherus BioSciences, Inc.

Coherus BioSciences develops cancer treatments primarily in the US. It has several programs in development, including UDENYCA, LOQTORZI, Casdozokitug, CHS-114, and CHS-1000. The company also offers YUSIMRY, a biosimilar to Humira for inflammatory diseases. Coherus collaborates with Junshi Biosciences on toripalimab, and has agreements with Surface, Adimab LLC, Bioeq AG, Genentech, Vaccinex, Novartis Institutes for Biomedical Research, and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was previously known as BioGenerics, Inc. before changing its name to Coherus BioSciences in 2012. It was incorporated in 2010 and is headquartered in Redwood City, California.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

0.8 USD

Potential

-100%

Strengths

Current Price to Earnings Ratio (3.27) is lower than the sector mean (91.15).
EV/EBIT (4.26) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	3.3
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0